Clinical problems in hemodialysis patients with autosomal dominant polycystic kidney disease

Koçyiğit, İsmail; Güngör, Özkan

doi:10.1111/sdi.12696

Cited by 4 publications

(2 citation statements)

References 135 publications

(294 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a major modifiable cardiovascular risk factors but also a factor in the progression of chronic kidney disease. The diagnosis of hypertension is made early International Journal of Nephrology and Kidney Failure and at a younger age compared to patients with essential hypertension [7,8]. In our study, the familial nature of the disease was established in 50% of patients, a result close to that found in Najoua with 57% of cases [6].…”

Section: Discussionsupporting

confidence: 67%

Autosomal Dominant Polycystic Kidney Disease: An Unknown Disease in Chad

G¹,

A²,

Soukaya³

et al. 2023

Int J Nephrol Kidney Fail

View full text Add to dashboard Cite

Introduction: Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic renal disease. After about ten years of evolution, it leads to a slow and progressive loss of kidney function eventually causing renal insufficiency and kidney failure. Few data exist on this pathology in Africa and Chad. The objective of this study was to analyze the epidemiological, diagnostic and therapeutic aspects of ADPKD. Methodology: This was a multicenter cross-sectional, descriptive and analytical study conducted over a period of 34 months in two hospitals in N’Djamena, Chad. All patients aged 15 years and above, having a family history of polycystic kidney disease, which were hospitalized or who were coming for consultation that met the unified criteria for ultrasonographic diagnoses (Ravine criteria modified by Pei) of ADPKD were included in the study. The clinical, paraclinical, therapeutic and evolutionary criteria for these patients had been studied. Results: There were a total of 26 cases of polycystic kidney disease that had a hospital prevalence of 1.16%. The average age was 42.4 years with extremes ranging from 15-70 years and a sex ratio of 1.3. The family survey had shown that parental consanguinity was present in 34.6% (n=9). The prevalence of hypertension was 53.8% (n=14). The mean serum creatinine was 45 mg/l with extremes ranging from 4.5 to 274.42 mg/l. It was noted that 65.3% (n=17) had chronic kidney disease with a GFR >30 mL/min/1.73m2 . During diagnosis 26.9% (n=7) had end-stage renal disease (ESRD), while 2 patients progressed to ESRD two years after diagnosis. One patient was hospitalized for chronic hemodialysis. No patient had received a kidney transplant and no patient had undergone a molecular biology and genetics study or had been treated with Tolvaptan. Conclusion: In Chad, the hospital prevalence of ADPKD was 1.16%, affecting young adults (average age of 42.4 years) with a male predominance. Management is usually late and remains limited to symptomatic treatment with complications such as chronic renal failure. Abbreviations: ADPKD: Autosomal Dominant Polycystic Kidney Disease, CRF: Chronic Renal Failure, ESRD: End-Stage Renal Disease, CVA: Cerebro Vascular Accident

show abstract

Section: Discussionsupporting

confidence: 67%

Autosomal Dominant Polycystic Kidney Disease: An Unknown Disease in Chad

G¹,

A²,

Soukaya³

et al. 2023

Int J Nephrol Kidney Fail

View full text Add to dashboard Cite

show abstract

“…97 However, PD is an anticoagulation-free treatment modality providing reduced risk of intracerebral bleeding in cases with the presence or possibility of intracranial aneurysms. 98 Accumulating evidence also showed that technique and/or patient survival is similar or better in ADPKD patients with PD in comparison to those with HD. 94,[99][100][101][102][103][104] As a result, there is little evidence that ADPKD is a contraindication for PD.…”

Section: Polycystic Kidney Diseasementioning

confidence: 99%

Peritoneal dialysis patient selection from a comorbidity perspective

Heimbürger

Lindholm

2020

Seminars in Dialysis

Self Cite

View full text Add to dashboard Cite

Chronic kidney disease (CKD) affects a large part of the population and represents a global public health problem as it is-especially in advanced stages of CKD-associated with major medical, societal, and economic burdens. 1 Despite preventive and therapeutic measures, CKD is often a progressive illness that may lead to end-stage renal disease (ESRD), 2,3 necessitating initiation of renal replacement therapy (RRT) by kidney transplantation, hemodialysis (HD), or peritoneal dialysis (PD). Although the best option for RRT is kidney transplantation, due to its advantages in terms of quality of life and survival, many patients cannot undergo transplantation because of lack of donors, older age, various comorbidities, or specific contraindications, and for these patients, choosing the best dialysis modality, PD or HD, according to their individual need and ability is an important task. 4 While clinical outcomes and life quality with PD are at least as good as with in-center HD, the latter is the dominating dialysis modality in almost all countries. This may be due to absolute contraindications to PD (which are few) or because of patient's preferences; however, many potentially eligible patients may not be considered to be suitable for PD or not even offered the option of PD because of conditions including comorbidities-some of which are the focus of this review-that rightly or wrongly are thought to represent a risk for complications. In addition, financial issues, in particular reimbursement policy, 5-7 has a strong impact on the use of PD, but lies outside the scope of this review.Compared to in-center HD, most studies indicate that PD associates with equivalent or during the first years of dialysis even better survival, 8 several specific medical advantages such as better preservation of residual renal function, 9 and, being a home-based dialysis therapy, socioeconomic advantages such as increased patient autonomy and reduced cost of therapy. 10 Nevertheless, even though as many as 70%-80% of patients may be eligible for PD at the time of dialysis initiation, [11][12][13] and there are no guidelines

show abstract